Figure 5 | British Journal of Cancer

Figure 5

From: Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial–mesenchymal transition (EMT) to mesenchymal–epithelial transition (MET) states

Figure 5

Eribulin treatment reduces metastasis and increases survival in MX-1 in vivo experimental metastasis model. (A) Numbers of lung nodules at day 15 after tail vein injection of MX-1 cells that had been pretreated with eribulin, 5-FU, or DMSO (n=5–7). *P<0.01 by Kruskal–Wallis Dunn’s multiple comparison test. (B) Representative lung images ( × 20 magnification) at day 15 after cell injection. (C) Survival of animals in the experimental metastasis assay (n=5–7).

Back to article page